All Pharma News
Neurogene Presenting NGN-401 Rett Syndrome Gene Therapy Safety Data

Neurogene Presenting NGN-401 Rett Syndrome Gene Therapy Safety Data
BUSINESSWIRE
22 Apr 2024
Share Share
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results
BUSINESSWIRE
18 Mar 2024
Share Share
Neurogene Announces Expansion for Enrollment of Rett Syndrome Gene Therapy Trial

Neurogene Announces Expansion for Enrollment of Rett Syndrome Gene Therapy Trial
BUSINESSWIRE
04 Mar 2024
Share Share
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
BUSINESSWIRE
16 Jan 2024
Share Share
Neurogene Announces Business Update and 2024 Outlook

Neurogene Announces Business Update and 2024 Outlook
BUSINESSWIRE
05 Jan 2024
Share Share
Neurogene Announces Closing of Merger with Neoleukin Therapeutics

Neurogene Announces Closing of Merger with Neoleukin Therapeutics
BUSINESSWIRE
19 Dec 2023
Share Share
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401

Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401
BUSINESSWIRE
30 Nov 2023
Share Share
Neurogene inks Neoleukin reverse merger to fund gene therapies

Neurogene inks Neoleukin reverse merger to fund gene therapies
Nick Paul Taylor FIERCE BIOTECH
18 Jul 2023
Share Share
FDA clears Neurogene`s IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease

FDA clears Neurogene`s IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
BIOSPACE
14 Sep 2021
Share Share
Neurogene Announces EMA Grants Orphan Drug Designation to CLN5

Neurogene Announces EMA Grants Orphan Drug Designation to CLN5
BUSINESSWIRE
29 Jun 2021
Share Share